Compare Illumina, Inc. (ILMN) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Keysight Technologies Inc — how do they compare? Illumina, Inc. trades at $192.93 (market cap $28.96B), while Keysight Technologies Inc trades at $344 (market cap $57.32B). The key difference: Keysight Technologies Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ILMN | KEYS | |
|---|---|---|
Market Cap | $28.96B | $57.32B |
Sector | Health | Technology |
52-Week High | $205.10 | $373.34 |
52-Week Low | $91.00 | $158.51 |
Enterprise Value | $30.32B | $57.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Keysight Technologies (KEYS) trades at $340.97, up 1.19% today, near its 52-week high. The stock shows strong momentum with bullish moving averages and consistent earnings beats, including Q1 2026 EPS of $2.87 versus $2.32 expected. Revenue for 2025 reached $5.38B with a net income margin of 17.31%. Recent news highlights product innovations like the APS-ONE-400 cybersecurity platform and collaborations with Intel and the European Space Agency, reinforcing growth prospects in 5G and defense markets.
Outlook remains positive with a consensus price target of $396.56, implying 16% upside, supported by 81% analyst buy ratings. Risks include elevated valuation multiples (P/E 54.91) and high RSI levels suggesting overbought conditions. Investors should monitor execution on 2026 revenue guidance of $6.1B and manage exposure to tech sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
